罗氏Roche Holdings（RHHBY）2010年年度报告「OTC」.pdf

1、Roche Annual Report2010Creating value for patientsSalesCore Earnings per ShareResearch and development 2Total employee remuneration Operating profit 2Total dividendIncome taxes 2mCHFmCHFmCHFmCHFmCHFmCHFmCHFNumber of employeesNet incomePatients on clinical trials 4Free cash flowEco-efficiency rate 5R

2、oche GroupIndex 2008=10047,47349,05145,61720102009200812.7812.3411.17CHF9,0509,5098,70420102009200811,93412,08011,12916,59116,27215,0682010200920085,69335,175 4,313 3,1353,2873,60420102009200880,65381,50780,0808,8918,51010,844mCHF201020092008327,804302,063277,6744,6998,8934,9792010200920080.4140.460

3、.387Price development of non-voting equity security(Genussschein)|in CHF200150100250300Roche non-voting equity securitySwiss Market Index(rebased)200820092010Key figures1 Keyfiguresindexedto2008=100.2 Coreresults.3 ProposedbytheBoardofDirectors.4 DevelopmentphaseItoIV.5 ForcalculationoftheEco-Effici

4、encyRatesee: nearly 24 million people worldwide,schizo-phrenia is a severe mental disorder that distorts the way a person thinks,acts,expresses emotions,per-ceives reality and relates to others.It is a lifelong disease that cannot be cured.On average it shortens life expectancy by 20 years due to th

5、e higher risk of suicide and also due to cardiovascular and pulmo-nary events.Because of negative symptoms,which usually have the greatest impact on quality of life,patients may be unable to live independently,hold jobs,establish personal relationships and manage every-day social situations.Many dru

6、gs developed to treat negative symptoms have failed in clinical trials,and the few available treatments offer only modest benefits.RG1678,a glycine reuptake inhibitor(GRI)developed at Roche,may be the first drug to treat the negative symptoms of schizophrenia.Representing an entirely novel approach,